How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little therapeutic progress during the past several decades and still the standard of care remains chemotherapy. Experimental discovery of molecular signatures including the ‘BRCAness’ highlighted the innate heterogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Hyun, Ahn, Jin-Hee, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950702/
https://www.ncbi.nlm.nih.gov/pubmed/29765774
http://dx.doi.org/10.1136/esmoopen-2018-000357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950702/
https://www.ncbi.nlm.nih.gov/pubmed/29765774
http://dx.doi.org/10.1136/esmoopen-2018-000357

Ejemplares similares